Thalassemia Treatment Market Research Report - Global Forecast till 2027

Thalassemia Treatment Market: Information by Type (Alpha-thalassemia, Beta Thalassemia), Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplants), End User (Hospitals and Clinics, Diagnostic Laboratories and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/7123-HCR | February, 2021 | Region : Global

Thalassemia Treatment Market Outlook


Thalassemia Treatment Market is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%. Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.


Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.


Thalassemia Treatment Market Influencers


Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the Thalassemia Treatment Market.


Market Drivers



  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.



  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.



  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the Thalassemia Treatment Market.



  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.


Market Restraints



  • Stringent regulatory policies

  • High treatment costs


Thalassemia Treatment Market Segmentation


By Type



  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.



  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.


By Treatment



  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.



  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.



  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.



  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.



  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the Thalassemia Treatment Market growth in this segment.


By End-User



  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.



  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.



  • Others: This segment includes research laboratories, educational institutes, among others.


By Region



  • Americas: The largest growing regional Thalassemia Treatment Market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.



  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.



  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.



  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.


Thalassemia Treatment Market Key Players



  • Novartis AG (Switzerland)

  • Bluebird Bio, Inc. (US)

  • Kiadis Pharma (Netherlands)

  • CELGENE CORPORATION (US)

  • Sangamo Therapeutics (US)

  • Acceleron Pharma, Inc. (US)

  • Gamida Cell (Israel)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Research Methodology for Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL THALASSEMIA TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Alpha-thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Beta Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Blood Transfusions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Iron Chelation Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Folic Acid Supplements

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Gene therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL THALASSEMIA TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Diagnostic laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL THALASSEMIA TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

10.1.3. Market Share Analysis

10.1.4. Major Growth Strategy in the Global Thalassemia Treatment Market

10.1.5. Competitive Benchmarking

10.1.6. Leading Player in terms of Number of Developments in Global Thalassemia Treatment Market

10.1.7. Key Developments & Growth Strategies

10.1.7.1. Product Launch

10.1.7.2. Merger & Acquisition

10.1.7.3. Joint Ventures

10.1.8. Major Players Financial Matrix

10.1.8.1. Sales & Operating Income 2018

10.1.9. Major Players R&D Expenditure 2018

11. COMPANY PROFILES

11.1. Novartis AG

11.1.1. Company Overview

11.1.2. PRODUCT Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Blueird Bio, Inc.

11.2.1. Company Overview

11.2.2. PRODUCT Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Kiadis Pharma

11.3.1. Company Overview

11.3.2. PRODUCT Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. CELGENE CORPORATION

11.4.1. Company Overview

11.4.2. PRODUCT Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Sangamo Therapeutics

11.5.1. Company Overview

11.5.2. PRODUCT Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Acceleron Pharma, Inc.

11.6.1. Company Overview

11.6.2. PRODUCT Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Gamida Cell.

11.7.1. Company Overview

11.7.2. PRODUCT Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Aspen Medical Products

11.8.1. Company Overview

11.8.2. PRODUCT Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Others

12. APPENDIX

12.1. References

12.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

• In section 10, only top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources

LIST OF TABLES

TABLE 1 GLOBAL THALASSEMIA TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL THALASSEMIA TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL THALASSEMIA TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 8 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 14 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 20 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 26 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 32 GLOBAL THALASSEMIA TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL THALASSEMIA TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL THALASSEMIA TREATMENT MARKET

FIGURE 4 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY TYPE, 2020(%)

FIGURE 5 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY TREATMENT, 2020(%)

FIGURE 6 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 8 AMERICAS: THALASSEMIA TREATMENT MARKET SHARE BY REGION, 2020(%)

FIGURE 9 NORTH AMERICA: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 10 EUROPE: THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 11 WESTERN EUROPE: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 12 ASIA-PACIFIC: THALASSEMIA TREATMENT MARKET SHARE, BY REGION, 2020(%)

FIGURE 13 MIDDLE EAST & AFRICA: THALASSEMIA TREATMENT MARKET SHARE, BY COUNTRY, 2020(%)

FIGURE 14 GLOBAL THALASSEMIA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020(%)

FIGURE 15 NOVARTIS AG: KEY FINANCIALS

FIGURE 16 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 17 NOVARTIS AG: REGIONAL REVENUE

FIGURE 18 BLUEBIRD BIO, INC.: KEY FINANCIALS

FIGURE 19 BLUEBIRD BIO, INC.: SEGMENTAL REVENUE

FIGURE 20 BLUEBIRD BIO, INC.: REGIONAL REVENUE

FIGURE 21 KIADIS PHARMA: KEY FINANCIALS

FIGURE 22 KIADIS PHARMA: SEGMENTAL REVENUE

FIGURE 23 KIADIS PHARMA: REGIONAL REVENUE

FIGURE 24 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 25 CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 26 CELGENE CORPORATION: REGIONAL REVENUE

FIGURE 27 SANGAMO THERAPEUTICS: KEY FINANCIALS

FIGURE 28 SANGAMO THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 29 SANGAMO THERAPEUTICS: REGIONAL REVENUE

FIGURE 30 ACCELERON PHARMA, INC.: KEY FINANCIALS

FIGURE 31 ACCELERON PHARMA, INC.: SEGMENTAL REVENUE

FIGURE 32 ACCELERON PHARMA, INC.: REGIONAL REVENUE

FIGURE 33 GAMIDA CELL: KEY FINANCIALS

FIGURE 34 GAMIDA CELL: SEGMENTAL REVENUE

FIGURE 35 GAMIDA CELL: REGIONAL REVENUE




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.